ArticleIrish journal of medical science2025
Enhanced diagnostic accuracy of type 1 diabetes mellitus through the combined use of serum β-catenin and HbA1c.
Article in Irish journal of medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundType 1 diabetes mellitus (T1DM) is due to the autoimmune destruction of pancreatic β-cells. Biomarkers of early diagnosis of T1DM are important to improve treatment and prevent complications. β-catenin, a key effector of the WNT signaling pathway, plays a critical role in the development of pancreatic β-cells. This study investigates the association between serum β-catenin protein and T1DM and evaluates its diagnostic performance compared to routine markers. MATERIAL AND
methodsThe study included 50 patients with T1DM aged 15-25 years and 30 healthy age- and gender-matched subjects (HS). All participants were evaluated with full history taking, thorough clinical examination, and laboratory evaluation of biochemical tests and glycemic markers. Serum β-catenin was measured using an enzyme-linked immunosorbent assay.
resultThere were significant differences in the concentration of β-catenin between T1DM and HS (P < 0.001). Gender, HbA1c, BU, and lipid profile were found to be significantly independently related to β-catenin levels (P < 0.05). β-catenin showed excellent discriminatory ability (AUC 1.0); the results revealed that the best cut-off value of β-catenin levels to predict T1DM was > 1.81 ng/ml.
conclusionThe results show that the concentration of β-catenin has the potential to diagnose T1DM. Further, larger studies are needed on whether β-catenin has a therapeutic role in T1DM.
Indexed as
Identifiers
40553355What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.